Participant flow14

How many started, completed or left each group, period by period.

1 to 14 of 14

Period	Milestone	Group	Participants
Overall Study	STARTED	CapeOx Plus Lapatinib	272
Overall Study	STARTED	CapeOx Plus Placebo	273
Overall Study	Primary Efficacy (PE) Population	CapeOx Plus Lapatinib	249
Overall Study	Primary Efficacy (PE) Population	CapeOx Plus Placebo	238
Overall Study	Safety Population	CapeOx Plus Lapatinib	270
Overall Study	Safety Population	CapeOx Plus Placebo	267
Overall Study	Ongoing: On Study Treatment	CapeOx Plus Lapatinib	1
Overall Study	Ongoing: On Study Treatment	CapeOx Plus Placebo	0
Overall Study	Ongoing: In Follow Up	CapeOx Plus Lapatinib	1
Overall Study	Ongoing: In Follow Up	CapeOx Plus Placebo	0
Overall Study	COMPLETED	CapeOx Plus Lapatinib	243
Overall Study	COMPLETED	CapeOx Plus Placebo	233
Overall Study	NOT COMPLETED	CapeOx Plus Lapatinib	29
Overall Study	NOT COMPLETED	CapeOx Plus Placebo	40

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00680901/flow